Controversy has once again found its way to the FDA as the polarizing vaccine regulator, Dr. Prasad, prepares to step down. Scheduled to leave at the end of April 2026, this departure has been confirmed by an FDA spokesperson and the Department of Health and Human Services (HHS). Dr. Prasad plans to return to a one-year sabbatical at the University of California – San Francisco, but let’s be real: one can only hope his replacement can handle the hot seat better.
His time at the FDA has been anything but dull. Prasad’s previous exit amid tensions over gene therapy decisions could easily qualify as a dramatic episode in a medical soap opera. After being ousted last July, he was reinstated just two weeks later to lead the Center for Biologics Evaluation and Research (CBER). Talk about a rollercoaster!
His tenure has been marked by significant accomplishments, such as reducing the clinical trials needed for drug approvals and launching a speedy drug review program. But with great power comes great controversy.
Dr. Prasad has been criticized for denying approvals for several rare disease medications and advocating for stricter vaccine oversight. His refusal to review Moderna’s mRNA flu vaccine application was overturned only after some serious White House pressure. Twelve former FDA commissioners even deemed his proposed standards as impossible. So, yeah, not exactly a crowd favorite. Additionally, his departure follows criticism over regulation of rare disease drugs, highlighting the contentious nature of his leadership.
Internally, things haven’t been much smoother. Employees have filed complaints about his management style, with tensions rising around decisions related to gene therapies and vaccines. It seems there’s never a dull moment.
His public persona as a critic of the pandemic response adds another layer of complexity to his role. As Dr. Prasad gets ready to exit, one can’t help but wonder what kind of legacy he leaves behind. A mix of innovation, tension, and controversy—sounds like a typical day at the FDA.
